Biotech · Private company
Phoenicis Therapeutics
Track this companyFree. Adds Phoenicis Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- PTM-001Phase 2 · Hidradenitis SuppurativaClinicalTrials.gov · fetched Nov 12, 2026
- PTW-002 10 mg/g gelPhase 2 · Dystrophic Epidermolysis BullosaClinicalTrials.gov · fetched Nov 12, 2026
- QR-313Phase 2 · Epidermolysis Bullosa Dystrophica, RecessiveClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 GenePHASE1_PHASE2 · UNKNOWN · started Apr 30, 2023ClinicalTrials.gov NCT05529134 · fetched Nov 12, 2026
- Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis SuppurativaPHASE2 · UNKNOWN · started May 5, 2022ClinicalTrials.gov NCT05020730 · fetched Nov 12, 2026
- A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 GenePHASE1_PHASE2 · TERMINATED · started Jul 2, 2018ClinicalTrials.gov NCT03605069 · fetched Nov 12, 2026